Labcorp’s Post

💡 What is the MindLight™ Antidepressant Response Test? Watch this quick clip to discover how our brain-derived biomarker test works and how it can support both patients and physicians in creating personalized treatment plans. #MindLightTest #PersonalizedMedicine #MentalHealth #CircularGenomics #Innovation #Antidepressants

Paul W. Noble, MD, discusses key unmet needs in idiopathic pulmonary fibrosis therapies in this K-Cast series. They highlight the potential for novel treatments to optimize patient outcomes and discuss how the GAP model can help determine patient prognosis. Watch the program here to learn more: https://bit.ly/3VYeOSZ #ManagedCare

🔬 The Power of Biomarker Testing in Advancing Health 🔬 As we navigate the complexities of modern healthcare, biomarker testing is a pivotal tool in our mission to improve patient outcomes and advance personalized medicine. At the Cholangiocarcinoma Foundation, we believe in this technology's transformative potential. Biomarker testing enables tailored treatment plans, leading to better health outcomes for our community. It's not just about identifying diseases—it's about understanding them at a molecular level to provide the most effective care possible. #Cholangiocarcinoma survivor Matt Reidy shares his story about how biomarker testing changed his course of treatment after he found out he had the MLH1 mutation. There is hope in research. Matt's story: https://lnkd.in/gAPm9k8f #HealthcareInnovation #BiomarkerTesting #PrecisionMedicine #BiomarkersMatter #CureCCA #CCAHope

Did you know that someone dies every three seconds from organ failure due to sepsis? Early detection is critical to saving lives. At Teledyne, we’re working with Canatu to develop a high-sensitivity multiplexing bio-sensing platform that can rapidly detect sepsis biomarkers and help predict organ failure. Want to learn more? Join us at MEDICA 2024 at Booth 8A N40, where we’ll be sharing insights into this technology and its potential to change patient care. #MEDICA2024 #TeledyneHealthcare #SepsisDetection Carsten Gollasch, PhD, MBA Caterina Taddei Mari Makkonen

Unlocking the future of patient care starts with tackling subclinical rejection. In this panel, we dive into the promising directions for biomarker research. Discover key insights into addressing this essential challenge—watch the full discussion here: https://ow.ly/iVUJ50U0FJ6 #SubclinicalRejection #KidneyHealth #TransplantInnovation

🚨📢 Publication Alert! 📢🚨 Our latest research explores innovative biomarkers for distinguishing between benign and malignant breast masses, aiding in early diagnosis and treatment decisions. 🩺🔍 Our study highlights the potential of triglyceride-glycemic index (TyG) and platelet-lymphocyte ratio (PLR) as adjunctive markers, offering cost-effective and accessible solutions for clinicians. 📈💉 Combining TyG and PLR significantly enhances predictive power, paving the way for improved patient care. 🌟🔬 These markers were chosen for their cost-effectiveness and practicality, making them invaluable in peripheral healthcare settings. 🏥💰Plus, they can aid in prioritizing referral services for patients with breast masses, potentially saving lives through early detection. 🩺✨ #BreastCancer #EarlyDetection #MedicalResearch #TyGIndex #PLR #HealthcareInnovation #ClinicalDecisionMaking 🩺💖 Read more at https://lnkd.in/gRaB42ga

Just Released: The EANO Guideline on molecular testing of meningiomas for targeted therapy selection! Evidence-based guidance for patient care & clinical trials, and show of areas for which additional research is warranted. Learn more: https://lnkd.in/e7NgkWM2 #EANO #EANOguideline #Meningioma #TargetedTherapy #ICOM

Excited to share this post featuring Professor Angela Dispenzieri, about the benefits of Mass Spectrometry.

🔬 Explore evolving treatments for NSCLC with HER2 mutations. 💡 Gain confidence in interpreting biomarker results, personalizing care plans, and addressing barriers to ensure seamless patient care. Learn more: http://ms.spr.ly/6047WNuU7 #NSCLC #PrecisionMedicine

📑 EANO European Association of Neuro-Oncology Guideline on molecular testing for Meningiomas for targeted therapy selection. 🧬 Meningiomas can express a wide range of molecular alterations and markers including  NF2, AKT1, SMO, SMARCE1, PIK3CA, CDKN2A/B, CDK4/6, TERT, TRAF7, BAP1, KLF4, ARID1/2, SUFU, PD-L1, SSTR2A, PR/ER, mTOR, VEGFR, PDGFR, as well as homologous recombination deficiency (HRD), genomic copy number variations, DNA methylation classes and combined gene expression profiles. 🎯 Based on the established ESMO ESCAT (European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets) evidence level criteria, unfortunately, no molecular target reached ESCAT I (“ready for clinical use”) classification and only mTOR pathway activation and NF2 alterations reached ESCAT II (“investigational”) classification, respectively. 💡 This highlights the need for future research and innovative trial design that incorporates molecular profiling that allows for the evaluation of targeted therapy in these tumors. #neuronc #medonc #meningiomas #eano #targeted #therapy #molecular #profiling #personalized #medicine